Noble Financial Keeps Agile Therapeutics (AGRX) at 'Buy'; Q2 Results Inline, Key Phase 3 Data Expected in Q4

August 9, 2016 12:04 PM EDT
Get Alerts AGRX Hot Sheet
Price: $2.37 -2.87%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 6 | Down: 10 | New: 6
Trade AGRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Noble Financial affirms Agile Therapeutics, Inc. (Nasdaq: AGRX) with a Buy rating and $15 price target after the company reported Q2 results late Tuesday.

Analyst Nathan Cali noted that results were largely as expected. The analyst also noted the following:

  • Expected phase III completion and planned phase II study slightly increases R&D estimates. R&D spend of $5.6 million slightly higher than $5.1 estimate, increasing full year R&D estimate from $20.2 million to $23.7 million to account for planned Phase II study
  • Additional pipeline asset may increase patient compliance. Current planning underway and plans to advance AG200-SP in Phase II trials Q1-2017; smaller, lower-dose application of Twirla use in fourth week of 28-day cycle, allows for continuous patch application; better contraception, compliance and reduced withdrawal bleeding
  • upcoming pivotal phase III data expected Q4-2016 and an NDA submission expected first half 2017, we estimate that the current cash balance $59.2 million is sufficient to extend operations into 2018

For an analyst ratings summary and ratings history on Agile Therapeutics click here. For more ratings news on Agile Therapeutics click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Noble Financial

Add Your Comment